House Bill 945 would create a new chapter in Title 54, Idaho Code, called the “AI Medical Services Act,” establishing a state licensing and regulatory framework for artificial intelligence used in clinical care. The bill defines “clinical AI service” broadly to include software or automated systems that diagnose, triage, treat, prescribe, monitor, or otherwise materially influence patient-specific clinical decisions, while excluding purely administrative, informational, and certain advisory tools. It creates a new licensed entity, the artificial intelligence augmented and autonomous service provider (AAASP), and sets up a Board of Autonomous Medical Practice to license, oversee, audit, discipline, and set rules for these providers.
The bill creates a tiered licensure system with base classes and autonomy modifiers, including provisional sandbox licenses and full licenses, and distinguishes among informational, advisory, supervised autonomous, and fully autonomous AI. It also sets transparency requirements for patients, including disclosures for supervised and autonomous AI care, and imposes duties of loyalty, clinical integrity, and auditability on higher-autonomy providers. Additional provisions address safety benchmarks, human-subjects review, insurance and reimbursement guidance, state provider identifiers, wind-down and continuity planning, and enforcement tools such as cease-and-desist orders and administrative fines.
In terms of state law impact, the bill would significantly expand Idaho’s professional licensing statutes by adding a new regulated category for AI-based clinical practice and by expressly waiving corporate-practice restrictions only as needed for AAASPs to operate and bill for authorized services. It would also direct the Department of Insurance and state health agencies to develop reimbursement and coverage guidance, while limiting state claims for federal matching funds unless federal guidance permits it. The bill attempts to preserve compliance with federal law, including HIPAA, FDA rules, ERISA, and controlled-substances law, and it states that it does not alter the scope of practice of human-licensed health professions.
The overall tone of the bill is strongly pro-innovation and pro-access, with the legislative findings emphasizing provider shortages, patient access, and responsible AI deployment. The bill also reflects a strong regulatory posture, requiring safety benchmarks, audits, insurance, bonding, and ethical review, while framing restrictions as needing to be narrowly tailored to documented patient-safety risks. Because there were no committee transcripts or recorded votes provided, there is no documented public debate in the supplied materials, but the text itself suggests an effort to balance innovation with patient protection.
The main points of contention likely concern whether Idaho should create a new licensure pathway for autonomous AI to practice medicine, how far that authority should extend, and whether the bill’s broad preemption of other licensing boards and its liability and reimbursement provisions go too far. Potential concerns also include patient safety, accountability for algorithmic decisions, the role of human oversight, and whether the bill could conflict with federal medical-device, reimbursement, or professional-regulation frameworks. Supporters would likely focus on access, shortage relief, and innovation, while critics may question the risks of autonomous clinical decision-making and the scope of state authorization for AI providers.
The bill would add a new Chapter 60 to Title 54 of the Idaho Code and create a comprehensive licensing, oversight, and enforcement regime for AI-delivered clinical services. It would authorize the Board of Autonomous Medical Practice to license AI providers, set safety standards, conduct audits, issue discipline, and coordinate with insurance and health agencies on reimbursement and coverage. It also would affect privacy, confidentiality, credentialing, and reimbursement laws by deeming licensed AAASPs health care providers for certain state-law purposes, while expressly limiting any implication for Medicare, Medicaid, or other federal payment programs unless federal guidance allows it.
The bill’s text reflects a generally favorable view of AI in health care, emphasizing access, innovation, and provider-shortage relief, while also building in substantial oversight and safety controls. Because no committee transcript or vote record was provided, there is no direct evidence of floor or committee sentiment beyond the bill’s own findings and structure. Based on the language, the measure appears designed to appeal to both innovation-minded and patient-safety-minded lawmakers, though its breadth suggests it could draw skepticism from those wary of autonomous medical practice.
Likely points of contention include whether AI systems should be allowed to independently diagnose, treat, triage, or prescribe; whether the new board should have exclusive authority over AI clinical services; and whether the bill’s liability, reimbursement, and corporate-practice waivers are too expansive. Another likely dispute is the balance between patient access and safety, especially the bill’s presumption that AI-enabled services are authorized unless a specific safety risk is shown, and its limits on other licensing boards’ ability to regulate lawful AAASP activity. Stakeholders most likely to raise concerns include human health professional boards, patient-safety advocates, insurers, and those focused on federal preemption and malpractice exposure.